The global Whole Exome Sequencing market size was valued at USD 220.69 million in 2022 and is expected to reach USD 528.84 billion by 2030 growing with a CAGR of 11.8% during the forecast period.
Whole Exome Sequencing (WES) is the genomic method for sequencing all of the genes in a genome with the dependable and sensitive detection of the coding variants (SNVs, Indels). The importance of using the whole-exome sequencing (WES) technique is advancing to identify modifications in growing proportions of the protein-coding exome.
Whole Exome Sequencing is widely used as next-generation sequencing (NGS) method that involves sequencing the protein-coding regions of the genome.
The whole-exome sequencing market has gained strength in terms of revenue over the past years. The quick adoption of leading-edge technologies over the healthcare industry, increasing knowledge of the benefits of whole-exome sequencing technology over the WES technology.
The governments are highly investing in healthcare research and development activities and the rising necessity for enhancing developed disease diagnostic methods flourish the Whole-Exome Sequencing market growth. The dwindling of costs is creating gold fever for market players.
The requirement to monitor pathogenic infections, cancer, and other chronic infirmities drives the whole-exome sequencing (WES) market growth. The WES is highly adopted because of the speed and cost factors fueling the market growth.
However, ethical issues related to privacy, confidentiality, and the return of results are some major issues associated with the whole-exome sequencing technology. The dependability of the consent of the patient is another factor hindering market growth. The dearth of skilled labor and the cost of the instrument is high diminishing the market growth.
As per the research report, the global Whole Exome Sequencing Market has been segmented and sub-segmented based on the technology, products, and services, applications, and end-users.
Sequencing by Synthesis
Ion Semiconductor Sequencing
By technology, the sequencing by synthesis segment is expected to have a quick growth in terms of revenue and a CAGR growth rate throughout the forecast period. The growing adoption of sequencing by synthesis method for WES is due to the advantages like exact base-by-base sequencing, small errors, detailed data for varied applications, and decreased possibility of repetitive nucleotides.
DNA Fragmentation End Repair
A-Tailing and Size Selection
Library Preparation Kits
Target Enrichment Kits
The services segment accounted for the highest share in the products and services WES market. The demand for high-throughput sequencing and data analysis services because of the benefits like progressive bioinformatics visualization and low-price sequencing and data management boom the market growth.
The data analysis and sequencing cover a broad range of services from experimental design to library generation helping researchers and scientists to overcome the restrictions of bio-informatics pertaining problems and save time and reduce expenditure.
The systems segment accounted for the largest share of 49.2% in 2022.
Kits segment is standing second in place with a CAGR rate of 20.75% during the forecasted period.
Drug Discovery and Development
Agriculture and Animal Research
By application, the diagnostics segment dominates the whole-Exome Sequencing market.
The personalized segment grows with a CAGR of 21.05% during the foreseeable period. Personalized medicine desires to provide customized treatments to individual patients. The demand for personalized medicine has created immense opportunities in the genetic medicine field.
Moreover, personalized medicines are currently focusing on the efficiency of patients with cancer and other rare genetic disorders.
Research Center, Academic and Government Institutions
Hospitals and Clinics
Pharmaceutical and Biotechnology Companies
Regionally, the largest share is accounted to hold by North America. The growth is due to the growing application of whole-exome sequencing in identifying very rare diseases. Around 1,148,200 persons aged 13years and above were diagnosed with HIV in the U.S, as per the Centers for Disease Control and Prevention (CDC). 207,600 individuals whose infections were not diagnosed.
Europe is projected to exist as the second-largest region for the whole-exome sequencing market. Europe is the leading region for cancer and HIV disease diagnostics and treatment. The frequency of HIV in adults ranges from 0.2% in central Europe and to more than 1% of the population. UNAIDS approximated that around 2.3 million people are diagnosed with HIV in Europe, in 2010. In Europe, nearly 4,229,662 cancer cases were registered in 2018, as per the International Agency for Research on Cancer.
However, the market for Whole-Exome Sequencing in Asia-Pacific is awaited to be the quickest-growing region. The growth in the region attributes to usual funds from the government and a huge volume of conferences related to whole-exome sequencing. The growth in research and development activities and strategic expansion and acquisition in research organizations throughout the appearing economies mount the market growth in the region. With the rise in the geriatric population, the market for whole-exome sequencing is said to have ample growth, especially in emerging countries like India, China, and Japan.
Latin American market for whole-exome sequencing is prophesied to escalate the whole-exome sequencing market growth. The number of HIV-diagnosed patients in quickly developing countries of the region fuel the market growth. Brazil is leading the market with significant growth. The growing influence of research in biotechnology and bioinformatics propel the market growth in the region.
The Middle East and African market for whole-exome sequencing are witnessed to have a significant share throughout the forecast period. emerging economies like Kuwait, Saudi Arabia, and UAE are likely to experience constant growth because of growth in the number of cancer cases, and booming government initiatives to advance patient care and supportable reimbursement policies.
Major key players in the market
1. Illumina, Inc. (U.S.)
2. Life Technologies (acquired by Thermo Fisher Scientific, Inc.) (U.S.)
3. Roche NimbleGen, Inc. (U.S.)
4. Agilent Technologies (U.S.)
5. BGI (Beijing Genomics Institute, China)
6. Eurofins Genomics, Inc. (Germany)
7. Sengenics (U.S.)
8. GENEWIZ, Inc. (U.S.)
9. Knome, Inc. (U.S.)
10. Macrogen, Inc. (South Korea)
11. Ambry Genetics (U.S.)
COVID-19 Impact On Whole Exome Sequencing Market
The sudden outbreak of the novel coronavirus (COVID-19) pandemic and maintaining social-distance norms and restrictions have strictly disturbed worldwide operations. The quick downfall in the economy has caused a slowdown in manufacturing, and production leading to the loss of employment.
The surfacing of diverse variants of the virus and increasing infection rates during the early waves and consecutive lockdowns have critically influenced operations and disrupted the supply chains. As the COVID-19 cases are surging, the life sciences segment benefits owing to the growing demand for in-vitro diagnostics products and a surge in research and development activities globally. Novel technologies like mRNA are likely to appear and shift the pharmaceutical industry. However, the whole-exome sequencing market is said to experience quick growth over the upcoming years.
Recent Market Developments
Chapter 1. Global Whole Exome Sequencing Market – Scope & Methodology
1.1. Market Segmentation
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. Global Whole Exome Sequencing Market – Executive Summary
2.1. Market Size & Forecast – (2021 – 2027) ($M/$Bn)
2.2. Key Trends & Insights
2.3. COVID-19 Impact Analysis
2.3.1. Impact during 2022 - 2027
2.3.2. Impact on Supply – Demand
Chapter 3. Global Whole Exome Sequencing Market – Competition Scenario
3.1. Market Share Analysis
3.2. Product Benchmarking
3.3. Competitive Strategy & Development Scenario
3.4. Competitive Pricing Analysis
3.5. Supplier - Distributor Analysis
Chapter 4. Global Whole Exome Sequencing Market Entry Scenario
4.1. Case Studies – Start-up/Thriving Companies
4.2. Regulatory Scenario - By Region
4.3 Customer Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. Global Whole Exome Sequencing Market - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. Global Whole Exome Sequencing Market – By Technology
6.1. Sequencing by Synthesis
6.2. Ion Semiconductor Sequencing
Chapter 7. Global Whole Exome Sequencing Market – By Products and Services
7.4. DNA Fragmentation End Repair, A-Tailing and Size Selection
7.5. Library Preparation Kits
7.6. Target Enrichment Kits
Chapter 8. Global Whole Exome Sequencing Market – By Application
8.3. Monogenic Disorders
8.6. Drug Discovery and Development
8.7. Personalized Medicine
8.8. Agriculture and Animal Research
Chapter 9. Global Whole Exome Sequencing Market – By End-Users
9.1. Research Center, Academic and Government Institutions
9.2. Hospitals and Clinics
9.3. Pharmaceutical and Biotechnology Companies
Chapter 10. Global Whole Exome Sequencing Market, By Geography - Market Size, Forecast, Trends & Insights
10.1. North America
10.2.7. Rest of Europe
10.3. Asia Pacific
10.3.2. South Korea
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Rest of the World
10.4.1. Middle East
10.4.3. South America
Chapter 11. Global Whole Exome Sequencing Market – Company Profiles – (Overview, Product Portfolio, Financials, Developments)
11.1. Company 1
11.2. Company 2
11.3. Company 3
11.4. Company 4
11.5 Company 5
11.6. Company 6
11.7. Company 7
11.8. Company 8
11.9. Company 9
11.10. Company 10
Every order comes with Analyst Support
We offer customization to cater your needs to fullest
We value Integrity, quality and authenticity the most